

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

PD APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 08/892,695 07/15/97 GRAY J 023070068930 **EXAMINER** HM12/0702 TOWNSEND AND TOWNSEND AND CREW JOHNSON, N TWO EMBARCADERO CENTER 8TH FLOOR **ART UNIT** PAPER NUMBER SAN FRANCISCO CA 94111-3834 1642 lb DATE MAILED: 07/02/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.

				
EXAMINER				
ART UNIT	PAPER NUMBER			
1642	16			
DATE MANUEL				

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

- This application contains sequence disclosures that are encompassed by 1. the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
- Any inquiry concerning this communication should be directed to Examiner 2. Nancy A. Johnson, Art Unit 1642, whose telephone number is (703)305-5860.
- Any questions regarding compliance with the sequence rules requirements 3. specifically should be directed to the departments listed at the bottom of the Notice to Comply.
- APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH 4. TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Nancy A. Johnson, Ph.D.

Patent Examiner, Group 1642

The nucleotide and/or amino acid sequence not comply with the requirements for such 1.825 for the following reason(s):	e disclosure contain na disclosure as se	ned in this appl et forth in 37 C	ication does FR 1.821 -
Y			
1. This application clearly fails	to comply with the	requirements of	37 CFR 1.821
1.825. Applicant's attention is direct	ed to these regulat	ions, published	at 1114 OG 29
May 15, 1990 and at 55 FR 18230, May 1, 1	.990.	•	>
2. This application does not conta	in, as a separate ;	part of the disc	losure on
paper copy, a "Sequence Listing" as requi	red by 37 CFR 1.821	(c).	
Not in proper i	Formal.		•
3. A copy of the "Sequence Listing	y" in computer reada	able form has no	ot been
submitted as required by 37 CFR 1.821(e).			
4. A copy of the "Sequence Listing	" in computer reada	able form has be	en submitted.
However, the content of the computer read			
of 37 CFR 1.822 and/or 1.823, as indicated Sequence Listing."	d on the attached c	opy of the mark	ed-up "Raw
5. The computer readable form that	has been filed with	.h .hi1:4	
•		-	
found to be damaged and/or unreadable as a Report. A substitute computer readable for 1.825(d).	orm must be submitte	ed as required l	by 37 CFR
		,	· ·
6. The paper copy of the "Sequence	Listing" is not th	e same as the c	omputer
readable form of the "Sequence Listing" as	required by 37 CF	R 1.821(e).	
		,	
7.			
Other:	·	- 	<u> </u>
3mmliank musk massis.			
Applicant must provide:			
$\forall $			
An initial or substitute computer re	eadable form (CRF)	copy of the "Se	quence
Listing" An initial or substitute paper conv	in proper for	mat	
An initial or substitute paper copy			lag an
amendment directing its entry into		round , as wer	1 45 4
A statement that the content of the			
and, where applicable, include no n 1.821(f) or 1.821(g) or 1.825(b) or	ew matter, as requi 1.825(d)	red by 37 CFR 1	821(e) or
For questions regarding compliance	with these requi	irements, ple	ase contact:
For Rules Interpretation, call (703) 308-1123		
For CRF submission help, call (703)	308-4212		
For PatentIn software help, call (7	U3) 557-0400		

CATIONS CONTAINING

NOTICE TO COMPLY WIT REQUIREMENTS FOR PATENT APPLICATIONS NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Please return a copy of this notice with your response.